INSM
NASDAQ · Biotechnology
Insmed Inc
$139.14
-4.84 (-3.36%)
Performance
1D
—
1W
—
1M
—
3M
-21.78%
6M
+1.54%
1Y
+77.16%
YTD
-21.44%
Open$144.42
Previous Close$143.98
Day High$145.52
Day Low$137.20
52W High$212.75
52W Low$60.40
Volume—
Avg Volume1.84M
Market Cap30.09B
P/E Ratio—
EPS$-6.40
SectorBiotechnology
Technical Indicators
Full analysis →
SMA 50
$168.11
Below
SMA 200
$139.54
Below
RSI (14)
54.8
Neutral
Trend
Golden Cross
Bullish
Analyst Ratings
Strong Buy
26 analysts
Price Target
+3.1% upside
Current
$139.14
$139.14
Target
$143.40
$143.40
$91.17
$143.40 avg
$177.14
Key Financials
| FY 2026 | FY 2025 | FY 2024 | |
|---|---|---|---|
| Revenue | 674.17M | 498.65M | 44.36B |
| Net Income | -1,419,427,818 | -944,885,381 | 1.08B |
| Profit Margin | -210.5% | -200.0% | 2.4% |
| EBITDA | -1,381,439,234 | -970,685,852 | 2.00B |
| Free Cash Flow | — | — | 843.11M |
| Rev Growth | +35.2% | +35.2% | +19.4% |
| Debt/Equity | 0.99 | 0.99 | 0.36 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $205.20 | +0.13% | 166.6 | 397.77B |
| AMGN | Amgen Inc | $348.43 | -0.38% | 24.4 | 188.06B |
| GILD | Gilead Sciences Inc | $138.11 | +0.56% | 20.0 | 170.34B |
| VRTX | Vertex Pharmaceuticals Inc | $448.62 | -0.58% | 29.2 | 115.53B |
| REGN | Regeneron Pharmaceuticals | $741.69 | +0.70% | 17.9 | 80.50B |
| ALNY | Alnylam Pharmaceuticals Inc | $308.05 | +0.45% | 139.7 | 43.84B |